233 related articles for article (PubMed ID: 23226097)
1. Role of proprotein convertases in prostate cancer progression.
Couture F; D'Anjou F; Desjardins R; Boudreau F; Day R
Neoplasia; 2012 Nov; 14(11):1032-42. PubMed ID: 23226097
[TBL] [Abstract][Full Text] [Related]
2. Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells.
D'Anjou F; Couture F; Desjardins R; Day R
Methods Mol Biol; 2014; 1103():67-82. PubMed ID: 24318887
[TBL] [Abstract][Full Text] [Related]
3. PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
Panet F; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Day R
Eur J Cell Biol; 2017 Aug; 96(5):469-475. PubMed ID: 28347547
[TBL] [Abstract][Full Text] [Related]
4. Pro-protein convertases (PCs) other than PC6 are not tightly regulated for implantation in the human endometrium.
Freyer C; Kilpatrick LM; Salamonsen LA; Nie G
Reproduction; 2007 Jun; 133(6):1189-97. PubMed ID: 17636173
[TBL] [Abstract][Full Text] [Related]
5. The proprotein convertases furin and PACE4 play a significant role in tumor progression.
Bassi DE; Mahloogi H; Klein-Szanto AJ
Mol Carcinog; 2000 Jun; 28(2):63-9. PubMed ID: 10900462
[TBL] [Abstract][Full Text] [Related]
6. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.
Longuespée R; Couture F; Levesque C; Kwiatkowska A; Desjardins R; Gagnon S; Vergara D; Maffia M; Fournier I; Salzet M; Day R
Transl Oncol; 2014 May; 7(3):410-9. PubMed ID: 24818756
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.
Bakrania A; Aubé M; Desjardins R; Sabbagh R; Day R
Can J Physiol Pharmacol; 2020 Jul; 98(7):477-481. PubMed ID: 32119574
[TBL] [Abstract][Full Text] [Related]
8. miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway.
Kang S; Zhao Y; Hu K; Xu C; Wang L; Liu J; Yao A; Zhang H; Cao F
Prostate; 2014 Aug; 74(11):1095-106. PubMed ID: 24913567
[TBL] [Abstract][Full Text] [Related]
9. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.
Couture F; Levesque C; Dumulon-Perreault V; Ait-Mohand S; D'Anjou F; Day R; Guérin B
Neoplasia; 2014 Aug; 16(8):634-43. PubMed ID: 25220591
[TBL] [Abstract][Full Text] [Related]
10. PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Yao Z; Sun B; Hong Q; Yan J; Mu D; Li J; Sheng H; Guo H
Drug Des Devel Ther; 2015; 9():5911-23. PubMed ID: 26604689
[TBL] [Abstract][Full Text] [Related]
11. PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
Couture F; Sabbagh R; Kwiatkowska A; Desjardins R; Guay SP; Bouchard L; Day R
Cancer Res; 2017 Dec; 77(24):6863-6879. PubMed ID: 28993410
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder.
Kim W; Zekas E; Lodge R; Susan-Resiga D; Marcinkiewicz E; Essalmani R; Mihara K; Ramachandran R; Asahchop E; Gelman B; Cohen ÉA; Power C; Hollenberg MD; Seidah NG
Mol Cell Biol; 2015 Nov; 35(21):3684-700. PubMed ID: 26283733
[TBL] [Abstract][Full Text] [Related]
13. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
Levesque C; Fugère M; Kwiatkowska A; Couture F; Desjardins R; Routhier S; Moussette P; Prahl A; Lammek B; Appel JR; Houghten RA; D'Anjou F; Dory YL; Neugebauer W; Day R
J Med Chem; 2012 Dec; 55(23):10501-11. PubMed ID: 23126600
[TBL] [Abstract][Full Text] [Related]
14. Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7.
Scamuffa N; Basak A; Lalou C; Wargnier A; Marcinkiewicz J; Siegfried G; Chrétien M; Calvo F; Seidah NG; Khatib AM
Gut; 2008 Nov; 57(11):1573-82. PubMed ID: 18664504
[TBL] [Abstract][Full Text] [Related]
15. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.
Levesque C; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Neugebauer WA; Day R
Oncotarget; 2015 Feb; 6(6):3680-93. PubMed ID: 25682874
[TBL] [Abstract][Full Text] [Related]
16. Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.
Couture F; Ly K; Levesque C; Kwiatkowska A; Ait-Mohand S; Desjardins R; Guérin B; Day R
Biomed Res Int; 2015; 2015():824014. PubMed ID: 26114115
[TBL] [Abstract][Full Text] [Related]
17. PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer.
Couture F; Wang L; Dufour F; Chabot-Maheux K; Ekindi Ndongo N; Sabbagh R; Day R
Sci Rep; 2022 Apr; 12(1):6066. PubMed ID: 35410344
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.
Mekdad N; Tran TMH; Desjardins R; Kwiatkowska A; Couture F; Day R
Sci Rep; 2022 Oct; 12(1):17489. PubMed ID: 36261691
[TBL] [Abstract][Full Text] [Related]
19. Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7.
Lissitzky JC; Luis J; Munzer JS; Benjannet S; Parat F; Chrétien M; Marvaldi J; Seidah NG
Biochem J; 2000 Feb; 346 Pt 1(Pt 1):133-8. PubMed ID: 10657249
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer.
Page RE; Klein-Szanto AJ; Litwin S; Nicolas E; Al-Jumaily R; Alexander P; Godwin AK; Ross EA; Schilder RJ; Bassi DE
Cell Oncol; 2007; 29(4):289-99. PubMed ID: 17641413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
